Colorectal cancer biologic therapy

Epidemiology and Biology of Colorectal Cancer Adjuvant Therapy of Colon Carcinoma Adjuvant Therapy of Rectal Carcinoma Future Trends in Combined Modality Therapy for Colorectal Carcinoma References... 

Kufer, P., Mack, M., and Gruber, R., 1996. Construction and biological activity of a recombinant bi-specific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol. Immunother. 45 193-197. 

IL-2 has been approved for the heatment of renal cell carcinoma and also has shown good activity in malignant melanoma. Both of these tumors are refractory to chemotherapy. IL-2 has also been used invesdgationally, both alone and in combinadon with LAK cells, with chemotherapy and with other biological response modifier s (BRM s) to d eat a variety of different cancers (e.g., head and neck carcinoma, colorectal cancer, cend al nervous system cancer etc). In addidon to cancer therapy, IL-2 has been used to d eat padents infected with human immunodeficiency virus and it has been used ex vivo to generate antiviral T cells which were reinfused into padents (Lewko and Oldham, 2003 Dorr, 1993). 

Despite Fluorouracil remains the main agent for the treatment of certain cancer types (i.e. colorectal) [23], it displays various side effects due to its nonspecific cytotoxicity, poor distribution to tumor sites, and serious limitations in effectiveness due to drug resistance. Apart from modulation of Fluorouracil biological action through combination therapies [7, 24], a number of drugs and clinical candidates acting as prodrugs of 1 and/or 4 were developed (Table 1). 

---